Ronald Greenberg, MD
Gastroenterology · New Hyde Park, NYNPI 1114006327
Payments from drug & device makers
Across 10 payments — averaging $89.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ERBE USA Inc$365
- Amgen$125
- UCB, Inc.$123
- Merck$121
- AstraZeneca$118
- Olympus America Inc.$24
- plus $23 from 2 others
What the payments were for
- Food & beverage$897100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ERBE USA Inc | 2 | $365 |
| Amgen | 1 | $125 |
| UCB, Inc. | 2 | $123 |
| Merck | 1 | $121 |
| AstraZeneca | 1 | $118 |
| Olympus America Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Althera Pharmaceuticals LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$897 in reported general payments places this provider in the 35th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf)Adalimumab | 13 | $88,550 |
| CreonLipase/Protease/Amylase | 28 | $53,519 |
| Mesalamine | 47 | $31,789 |
| LinzessLinaclotide | 19 | $19,215 |
| Mesalamine ErMesalamine | 18 | $7,680 |
| Balsalazide Disodium | 11 | $4,368 |
| Pantoprazole Sodium | 165 | $2,883 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 37 | $2,191 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 12 | $2,044 |
| Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 21 | $1,674 |
| Esomeprazole Magnesium | 37 | $1,665 |
| Tenofovir Disoproxil Fumarate | 18 | $1,612 |
| Omeprazole | 126 | $1,451 |
| Mercaptopurine | 13 | $1,249 |
| Famotidine | 41 | $324 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in New Hyde Park
- Lev GinzburgNew Hyde Park$620K
- Ian StorchNew Hyde Park$370K
- Michael GerdisYonkers$11.9M
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Igor GrosmanBrooklyn$2.8M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.